Ardelyx is an American biopharmaceutical company that develops and sells medicines for the treatment of kidney and cardiorenal diseases. It was incorporated in 2007 and is headquartered in Fremont, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Ardelyx news
06.05.2022
Ardelyx's GAAP loss for 3 months of 2022 was $28.071 million, down 15.3% from $33.155 million in the previous year. Revenue decreased 14.1 times to $0.468 million from $6.582 million a year earlier.
Source: 
ir.ardelyx.com
ir.ardelyx.com
01.03.2022
Ardelyx's GAAP loss for 2021 was $158.165 million, up 67.7% from $94.313 million in the previous year. Revenue increased 33.4% to $10.097 billion from $7.571 billion a year earlier.
Source: ir.ardelyx.com
ir.ardelyx.com
15.11.2021
Ardelyx's GAAP loss for 9M 2021 was $121.931 million, up 86.3% from $65.437 million in the previous year. Revenue increased 57.4% to $9.068 million from $5.762 million a year earlier.
Source: ir.ardelyx.com
ir.ardelyx.com
General information
| Company name | Ardelyx |
|---|---|
| Tags | #biotechnology, #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 34175 Ardenwood Boulevard Fremont, CA 94555 United States |
| Mailing address | 34175 Ardenwood Boulevard Fremont, CA 94555 United States |
| Website | ir.ardelyx.com |
English (US) 